127 related articles for article (PubMed ID: 12921943)
1. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Giles FJ; Fracasso PM; Kantarjian HM; Cortes JE; Brown RA; Verstovsek S; Alvarado Y; Thomas DA; Faderl S; Garcia-Manero G; Wright LP; Samson T; Cahill A; Lambert P; Plunkett W; Sznol M; DiPersio JF; Gandhi V
Leuk Res; 2003 Dec; 27(12):1077-83. PubMed ID: 12921943
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson LE; O'Brien S
J Clin Oncol; 1998 Jul; 16(7):2321-31. PubMed ID: 9667246
[TBL] [Abstract][Full Text] [Related]
6. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Zeidner JF; Karp JE; Blackford AL; Smith BD; Gojo I; Gore SD; Levis MJ; Carraway HE; Greer JM; Ivy SP; Pratz KW; McDevitt MA
Haematologica; 2014 Apr; 99(4):672-8. PubMed ID: 24362550
[TBL] [Abstract][Full Text] [Related]
11. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase.
Fox RM
Pharmacol Ther; 1985; 30(1):31-42. PubMed ID: 3915820
[TBL] [Abstract][Full Text] [Related]
12. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.
Finch RA; Liu MC; Cory AH; Cory JG; Sartorelli AC
Adv Enzyme Regul; 1999; 39():3-12. PubMed ID: 10470363
[TBL] [Abstract][Full Text] [Related]
13. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
14. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Matsumoto J; Kiesel BF; Parise RA; Guo J; Taylor S; Huang M; Eiseman JL; Ivy SP; Kunos C; Chu E; Beumer JH
J Pharm Biomed Anal; 2017 Nov; 146():154-160. PubMed ID: 28881312
[TBL] [Abstract][Full Text] [Related]
15. Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.
Feng Y; Kunos CA; Xu Y
Biomed Chromatogr; 2015 Sep; 29(9):1380-7. PubMed ID: 25677991
[TBL] [Abstract][Full Text] [Related]
16. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
17. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.
Martin LK; Grecula J; Jia G; Wei L; Yang X; Otterson GA; Wu X; Harper E; Kefauver C; Zhou BS; Yen Y; Bloomston M; Knopp M; Ivy SP; Grever M; Bekaii-Saab T
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e475-81. PubMed ID: 22818416
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
20. A new era for ribonucleoside reductase inhibition.
Giles FJ
Leuk Res; 2007 Sep; 31(9):1163-4. PubMed ID: 17416414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
